Topics:
Gastrointestinal Cancers • Medical Oncology
How do you decide what to use for 2nd line treatment of liver-predominant metastatic neuroendocrine tumor that has progressed on a somatostatin analog?
How do you weigh the recently presented/published data from the NETTER-1 and RADIANT-4 trials in your decision making?
Answer from: Medical Oncologist at Academic Institution
Following progression on an SSA, there are a number of options and they differ depending on primary site and whether or not the tumor is functional (ie. secreting a hormone that causes symtoms of hormone excess. I will outline some scenarios below:1) For patients with non-functional liver-predomina...
Sign in or Register to read more